| Monoamine oxidase inhibitors and neuroprotective mechanisms | Dmitriy MATVEYCHUK, Erin M. MACKENZİE, Darrell D. MOUSSEAU, Serdar M. DURSUN, Glen B. BAKER | 293–296 |
| Effect of lateralization on motor and mental speed in bipolar disorder | Murat İlhan ATAGÜN, Cahit KESKİNKILIÇ, Özlem Devrim BALABAN, Dilek YEŞİLBAŞ, Cüneyt EVREN | 297–306 |
| Examination of outliers in bioequivalence studies | Gülcan DAĞHAN, Durdu KARASOY | 307–312 |
| Evaluation of the incidence of leukopenia and agranulocytosis in patients receiving combined clozapine and other antipsychotics | Osman SALİS, Abdullah AKPINAR | 313–319 |
| The prevalence of metabolic syndrome parameters among bipolar disorder outpatients on lithium monotherapy | Erhan KURT, Abdullah GENÇ, İsmail ÖZVER, Dilek YEŞİLBAŞ, Tevfik KALELİOĞLU, Esra Sena GENÇ, Akif TAŞDEMİR, Kürşat ALTINBAŞ | 320–324 |
| Effect of ferritin on short-term treatment response in attention deficit hyperactivity disorder | Kerim M. MÜNİR, Esra COP, Pınar ÖNER, Özgür ÖNER | 325–331 |
| Use of clock drawing test as a screening tool for cognitive status evaluation in middle-aged patients with depressive disorder | Fatma Özlem ORHAN, Mehmet Fatih KARAASLAN, Ufuk Güney ÖZER, Mustafa ÇELİK, Hasan Çetin EKERBİÇER | 332–339 |
| The investigation of validity and reliability of the Turkish version of the Brief Self-Control Scale | Numan KONUK, Melike NEBİOĞLU, Yüksel EROĞLU, Sırrı AKBABA | 340–351 |
| Neuroleptic malignant syndrome during the use of extended release quetiapine: a case report | Gülden Eser KARLIDAĞ, İsmail DEMİREL, Cemal ÜSTÜN, Fatma AKYÜZ, Serap OFLAZ | 352–354 |
| High dose paroxetine-induced galactorrhea with normal serum prolactin level: a case report | Oğuz KARAMUSTAFALIOĞLU, Bahadır BAKIM, Şencan SERTÇELİK | 355–356 |
| Quetiapine treatment for psychosis in friedreich's ataxia | Mehmet YAMAN, Serdar ORUÇ, Özge Yılmaz KÜSBECİ, Güray GÜLSEREN, Ömer GEÇİCİ | 357–358 |
|